Potential Analysis of the Decrease and the Selection Rate of the Centralized Procurement of Chinese Patent Medicines

Recently, the National Medical Insurance Administration made a unified deployment and coordination of the centralized procurement of local alliances

Following the centralized procurement of Chinese patent medicines by the 19-province alliance in Hubei, the centralized procurement of Chinese patent medicines by the Guangdong Alliance has further enriched the experience for the subsequent centralized procurement of Chinese patent medicines

The centralized procurement of Chinese patent medicines by Guangdong Alliance has been quoted in the first ten days of this month, and the results of the proposed selection have been announced.

01 Engagement rate

A total of 663 varieties of Chinese patent medicines were involved in the Guangdong alliance, of which only 87 were not quoted, and 576 varieties were quoted.

This time, a total of 313 pharmaceutical companies were involved, of which only 38 did not make an offer, and 275 made an offer, with a participation rate of 87.

In short, the participation rate of this company is still very high

02 Selection rate

A total of 663 varieties of proprietary Chinese medicines have passed the declaration of the Guangdong Alliance, including 45 exclusive products, 276 non-exclusive A purchase orders, and 342 B purchase orders.

03 Proposed drop rate

According to the calculation of Yilian Zhaocai based on the officially announced highest effective declared price/highest daily average cost, there are 112 products to be selected this time, with an average decrease of 37.

There are 14 products with the largest decline (80%-100%), accounting for only 13%, of which 12 products have a decline of more than 85%, and the largest decline is the children's Kechuanling granules of Hainan Haili Pharmaceutical Co.

There are 19 products with a decline of 60% to 80%, accounting for 17%

Most of the declines in centralized procurement this time are within 40%.

04 Proposed selection drop

1.

According to Fengyun Yaotan’s calculations, the non-exclusive group B has the largest average decline, with an average decline of 84.

2.

A purchase order has a total of 278 products to be selected, with an average decline of 47.

A total of 326 products of non-exclusive drugs are to be selected, with an average decline of 60%, and the distribution of decline is relatively even.

3.
Group B, the distribution of the decline in the varieties that need to be leveled

Purchase order B has a total of 83 products to be selected, with an average drop of 82.
58%, nearly double the average drop of 47.
97% in purchase order A.
Only 12% of the products have a drop of less than 50%, and 58% of the products have a drop of 90%.
above
.

This proposed/alternative product needs to be linked to the lowest selected price for provincial-level procurement with the same general name and the same dosage form of the same enterprise, and the average daily dosage is large (or the area of ​​rubber ointment is small/the amount of gel agent is small/the amount of spray agent is small) The price corresponding to the specification of small) should be lower than the price corresponding to the specification of small average daily dosage (or large area of ​​rubber plaster/large amount of gel agent/large amount of spray agent), and those higher than those need to be leveled
.
Among them, as many as 30% of the varieties with a decline between 60% and 70% need to be leveled
.

4.
Exclusive drop distribution

A total of 35 exclusive drugs are to be selected in this centralized procurement, with an average drop of 18%.
The overall drop is small, and the drop is basically below 50%.
The highest drop is Xianling Gubao from Sinopharm Tongjitang (Guizhou) Pharmaceutical Co.
, Ltd.
Capsules (0.
5g), a decrease of 51.
6%
.

Indicators such as enterprise participation rate, selection rate, and decline rate will also have reference significance for the comprehensive promotion of centralized procurement of Chinese patent medicines
.